Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) revealed on Tuesday that it has entered into a strategic partnership with Lynx Analytics to accelerate the discovery of small molecule therapies targeting sarcopenia, a progressive condition marked by muscle loss in older adults.

This collaboration aims to address a major unmet medical need, as no therapies for sarcopenia are currently approved by the US Food and Drug Administration (FDA).

Through the partnership, Biophytis will integrate its expertise in age-related disease biology with Lynx Analytics' artificial intelligence capabilities to enhance the efficiency of drug development.

Key objectives include mining biomedical data, expediting preclinical validation through in silico modelling, and building a pipeline of drug candidates focused on muscle preservation and regeneration.

The partnership is expected to streamline candidate selection and accelerate the development of therapies aimed at improving quality of life for individuals affected by sarcopenia. It reflects a broader trend toward using AI to transform pharmaceutical research and development, particularly in age-related conditions.